/

TARS

Tarsus Pharmaceuticals, Inc.Open

73.78−0.62 −0.83%USD

NasdaqGS · as of Oct 13, 10:16 ET · 15m delay

Open

74.50

Prev close

74.40

Day range

73.1474.65

52-week range

53.8991.53

Volume

33.84K0.04×

Mkt cap

3.45B

P/E ttm

—

Fwd P/E

-204.94

EPS ttm

-1.08

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−19.39%

Price Chart

Yahoo Finance · delayed

TARSOct 13, 2026O 74.50H 74.64L 73.14C 73.78−0.62 (−0.83%)Vol 33.84K

SMA 5074.42
SMA 20068.31

1Y change +5.19% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

TARS Tarsus Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −0.45%
1 month: −6.97%
3 months: +31.49%
6 months: −0.04%
Year to date: −9.89%
1 year: +4.89%

Valuation & ownership

Market cap: 3.45B
Enterprise value: 2.90B
P/E (ttm): —
Forward P/E: -204.94
PEG ratio: —
Price / book: 9.21
Price / sales (ttm): 5.69
EV / EBITDA: -62.86
EPS (ttm): -1.08
EPS (forward): -0.3600
Beta (5y monthly): 0.45
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 46.79M
Float: 32.74M
Short % of float: 13.37%
Short ratio (days): 7.31
Held by insiders: 2.69%
Held by institutions: 99.75%
Avg volume (3m): 846.50K
50-day average: 74.17
200-day average: 68.36
52-week change: +4.89%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 46.6
vs 50-day SMA: −0.86%
vs 200-day SMA: +8.00%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 3.82%
Realised vol (20d, ann.): 31.0%
From 52-week high: −19.39%
From 52-week low: +36.91%

ANR

Analyst Consensus

10 analysts

Consensus

—

Mean target

99.50

+34.86% implied

Low 84.00Median 100.00High 116.00

Recommendation trend

Now10 / 0 / 0
1m ago7 / 0 / 0
2m ago

DES

About Tarsus Pharmaceuticals, Inc.

Yahoo Finance profile

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 370
Headquarters: Irvine, CA, United States
Website: tarsusrx.com
Officers: Dr. Bobak R. Azamian M.D. Co-Founder, President, CEO & Chairman
Mr. Jeffrey S. Farrow CPA

SEAS

Seasonality · TARS

2020–2026 · monthly returns

Strongest month Oct +13.52%Weakest month Mar −4.79%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-21.2	17.0	-7.1	-9.3	-6.6	6.0	-6.2	25.7	5.9	-6.1			−9.9%
2025	-2.9	-17.3	15.5	1.1	-17.3	-5.7	-4.2	50.9	1.5	15.8	16.2	2.4	+47.9%
2024	34.5	40.3	-4.9	-13.5	4.9	-17.5	-10.6	11.6	21.3	35.3	17.9	5.6	+173.4%
2023	7.5	-1.7	-18.9	18.7	12.3	7.9	21.8	-20.4	1.5	-19.9	16.1	22.5	+38.1%
2022	-10.8	-12.2	-4.6	8.9	-24.9	6.2	2.9	2.4	11.3	7.6	-8.7	-12.8	−34.8%
2021	-8.8	-3.8	-11.1	-4.7	8.5	-13.0	-22.1	17.4	-18.7	28.8	-4.2	-15.4	−45.6%
2020											18.2	71.0	+102.2%

INSD

Insider Activity · TARS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

47.4K shares

Sells, 6 months

102.4K shares

Net shares

−55.1K

Net change in insider shares

−4.50%

Date	Insider	Transaction	Shares	Value
Sep 14, 2026	Link William JDirector	Sale at price 78.33 - 80.01 per share.	12.5K	$979.74K
Sep 14, 2026	Link William JDirector	—	201	—
Sep 14, 2026	Pyott David E IDirector	—	201	—
Sep 3, 2026	Neervannan SeshadriChief Operating Officer	Sale at price 85.00 per share.	4.6K	$387.94K
Sep 3, 2026	Azamian Bobak RChief Executive Officer	Sale at price 90.27 - 91.27 per share.	10K	$905.60K
Sep 3, 2026	Lin Elizabeth YeuOfficer	Sale at price 85.00 - 90.00 per share.	14K	$1.22M
Sep 1, 2026	Azamian Bobak RChief Executive Officer	Sale at price 80.06 per share.	10K	$800.60K
Sep 1, 2026	Lin Elizabeth YeuOfficer	Sale at price 73.86 - 80.00 per share.	11.6K	$897.99K
Jun 16, 2026	Azamian Bobak RChief Executive Officer	Sale at price 61.24 - 61.81 per share.	10K	$615.49K
Jun 15, 2026	Farrow Jeffrey SChief Financial Officer	Sale at price 60.95 per share.	14.4K	$877.44K
Jun 14, 2026	Farrow Jeffrey SChief Financial Officer	—	27.9K	—
Jun 14, 2026	Link William JDirector	Sale at price 61.97 - 62.94 per share.	12.5K	$776.50K
Jun 14, 2026	Goodrich KatherineDirector	Sale at price 62.08 per share.	3K	$183.38K
Jun 11, 2026	Yarno Wendy LDirector	—	3K	—
Jun 11, 2026	Morrison Scott William CpaDirector	—	3K	—
Jun 11, 2026	Link William JDirector	—	3K	—
Jun 11, 2026	Chaudhuri BhaskarDirector	—	3K	—
Jun 11, 2026	Goldberg Andrew DDirector	—	3K	—
Jun 11, 2026	Goodrich KatherineDirector	—	3K	—
Apr 23, 2026	Pyott David E IDirector	—	1.4K	—

13F

Investors Holding TARS

latest 13F filings of 29 followed managers

Investors holding TARS
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$585.3K	0.00%	9.30K	−87%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

TARS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

TARS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Tarsus Pharmaceuticals, Inc.

Seasonality · TARS

Insider Activity · TARS

Congress Trades · TARS

Investors Holding TARS

Investors Holding TARS

Congress Trades · TARS

Insider Activity · TARS

Seasonality · TARS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Tarsus Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News